Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:27 2025-06-20 EDT			5-day change	1st Jan Change
94.89 ^CHF	-0.34%		-2.34%	+6.98%

06-19	NOVARTIS AG : Deutsche Bank maintains a Buy rating	ZD
06-19	Swiss trade surplus at CHF 3.831 bln in May	RE

NOVARTIS AG : UBS reiterates its Buy rating

Published on 2024-05-31 at 13:32, updated on 2024-05-31 at 14:19

UBS analyst Matthew Weston maintains his Buy rating on the stock. The target price is unchanged at CHF 108.

Latest news about Novartis AG

NOVARTIS AG : Deutsche Bank maintains a Buy rating	06-19	ZD
Swiss trade surplus at CHF 3.831 bln in May	06-19	RE
Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	06-17	MT
Trump Administration to Consider Pharma Advertising Crackdown	06-17	MT
Trump Administration to Consider Pharma Advertising Crackdown, Bloomberg reports	06-17	MT
NOVARTIS AG : UBS sticks Neutral	06-16	ZD
Swiss Market Index Close Little Changed; Novartis Shares Rise	06-12	MT
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH	06-12	MT
Novartis: Fabhalta approved for a new population	06-12	CF
NOVARTIS AG : Berenberg reiterates its Neutral rating	06-12	ZD
Novartis' Fabhalta Shows Reduced Hemoglobin Levels in Late-stage Trial	06-12	MT
Novartis Says Fabhalta® Shows Statistically Significant And Clinically Meaningful Improvements In Hemoglobin In New Population Of Patients With Pnh	06-12	RE
Novartis Fabhalta(R) shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH	06-12	DJ
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	06-11	DJ
New purchases in the European Investor portfolio	06-10
NOVARTIS AG : Deutsche Bank gives a Buy rating	06-09	ZD
Otsuka's kidney disease therapy trial results heat up battle with rival Vera	06-06	RE
Further market approval for Formycon's Lucentis biosimilar - share price rises	06-05	DP
Formycon receives market approval in Brazil for Lucentis biosimilar	06-05	DP
Health insurers in favor of cost containment for drug spending	06-03	DP
Swiss Shares in Red as Trade Worries Overtake Q1 GDP Growth Beat	06-02	MT
Novartis Reports New Data From Phase 2 Trial of Kisqali in Breast Cancer	06-02	MT
Novartis Says Pluvicto Shows Benefit in Early Prostate Cancer Study	06-02	MT
Novartis Announces Topline Results from Pre-Specified Interim Analysis of the Phase III PSMAddition Trial	06-02	CI
European Midday Briefing : Stocks Mostly Drop as Trade Tensions Flare	06-02	DJ

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

07-16 - Q2 2025 Earnings Release

More about the company